Navigation Links
Verus Pharmaceuticals Announces Promotion of Robert W. Keith to Chief Executive Officer
Date:11/12/2007

SAN DIEGO, Nov. 12 /PRNewswire/ -- Verus Pharmaceuticals, Inc., a pediatric-oriented specialty pharmaceutical company, announced today that Robert W. Keith has been promoted to President & Chief Executive Officer. Prior to the promotion, Mr. Keith served as President & Chief Operating Officer. As a result of the promotion, Cam L. Garner now will serve exclusively as Executive Chairman.

"We are excited to announce this well-deserved promotion," said Cam L. Garner. "As a co-founder of Verus, Bob has played a critical role in the development and evolution of the company from day one to the present, including our recently announced transaction with AstraZeneca."

"I am honored to take the reins from Cam at this point in time and lead the company forward as we continue to build value in our commercial franchise and accelerate our efforts on our emerging development programs," said Robert W. Keith.

The composition of the Board of Directors will not change with the promotion of Mr. Keith. In addition to Mr. Garner and Mr. Keith, the other current members include James C. Blair, Alex E. Barkas, Jean-Pierre Naegeli, Nicholas J. Simon, David F. Hale, and Erle T. Mast.

About Verus

Verus Pharmaceuticals is dedicated to improving the lives of children and those who care for them. Verus is building a portfolio of products for the unmet medical needs of children through acquisitions and alliances, with an initial focus on the treatment of asthma, allergies, and related diseases and conditions. Verus is differentiated by its pediatric orientation and its strong financial position and experienced management team, which allows the company to capitalize on an extensive network to build its product portfolio and pursue complementary transactions. The company's rigorous, disciplined approach to strategic decision-making and core competencies in development and commercialization is expected to provide significant value to its partners. More information about Verus is available on the company's corporate website at http://www.veruspharm.com.

Verus(R) is a registered trademark of Verus Pharmaceuticals, Inc.

Forward-Looking Statements

Verus Pharmaceuticals cautions you that statements included in this press release that are not a description of historical facts may be forward-looking statements. The inclusion of forward-looking statements should not be regarded as a representation by Verus that any of its plans will be achieved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in Verus' business including, without limitation, statements about: its ability to identify appropriate acquisition, licensing, or co-development and/or promotion candidates in the future or be able to take advantage of the opportunities it identifies; difficulties or delays in developing, obtaining regulatory approval, manufacturing and commercializing its products; unexpected performance or side effects of its products that could delay or prevent development or commercialization, or that could result in recalls or product liability claims; the scope and validity of patent protection for its products; competition from other pharmaceutical companies; and its ability to obtain additional financing to support its operations. All forward-looking statements are qualified in their entirety by this cautionary statement and Verus undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

Company Contact: Media Contact:

Robert W. Keith Amy Caterina

President & Chief Executive Officer Corporate Communications

Verus Pharmaceuticals, Inc. Verus Pharmaceuticals, Inc.

rkeith@veruspharm.com acaterina@veruspharm.com

858-436-1615 858-436-1623


'/>"/>
SOURCE Verus Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Verus Pharmaceuticals Announces Divestiture of Pediatric Asthma Development Programs to AstraZeneca
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
7. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
8. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
9. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
10. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
11. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... Viejo, CA (PRWEB) , ... May 02, 2016 , ... ... in Final Cut Pro X. Pick and choose from a variety of electric styles ... with color swabs. Users can customize shadow, dof blur, three dimensional rotation, and much ...
(Date:5/2/2016)... , ... May 02, 2016 , ... Pets bring laughter, ... token of appreciation, pet owners celebrate National Pet Week, which falls on the first ... remind pet owners to cherish the human-animal bond and recognize responsible pet ownership. Pet ...
(Date:5/2/2016)... ... May 02, 2016 , ... Eating Recovery Center’s Insight ... mood and anxiety disorders, has rebranded its eating disorder program under a new name: ... disorder treatment facility on May 16. , To celebrate, ERC Chicago will host ...
(Date:5/2/2016)... ... 2016 , ... In honor of National Physical Fitness and Sports Month in ... their fitness journey on social media. , The foot care company, which specializes ... product voucher each week during May to one winner. , “Whether the goal is ...
(Date:5/2/2016)... ... May 02, 2016 , ... Dr. Philip Shindler, dentist in Agoura Hills ... In the past, many necessary dental treatments could require multiple appointments to complete. This ... and extra chair time. Not only could this be inconvenient, but it could also ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)...  Forté Elements, LLC (Forté) is excited to announce the launch of its Mediceutical ... needs of recovery for a variety of clinical conditions. Founded in 2013, Forté spent ... http://photos.prnewswire.com/prnh/20160502/362548 Logo -  http://photos.prnewswire.com/prnh/20160502/362547LOGO ... ... ...
(Date:5/3/2016)... , May 3, 2016 ... bekannt, dass sie einen entscheidenden Meilenstein durch ... Ein Aufruf zum Handeln, um Patientenresultate  bei ... trägt zu Fortschritten im Verständnis der Hepatischen ... ein Bewusstsein für Hepatische Enzephalopathie in der ...
(Date:5/2/2016)... Economies with Fastest Real GDP Annual Percentage Change, 2015  Real ... , Source: IMF and TechSci Research   According ... , Russia , India , ... fastest GDP growth during the first decade of the 21 st century. ... Brazil and Russia , along with policy uncertainty ...
Breaking Medicine Technology: